Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Explains How Generic Firms Will Self-Identify Facilities Under New User Fee Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Guidance on meeting the new self-identification requirement is one of several GDUFA-related announcements issued by FDA Aug. 22. The agency will hold a public meeting Sept. 21 to solicit comments on user fee program implementation issues.

Advertisement

Related Content

GDUFA Facility Self-Identification Pace Slow As Deadline Neared
Generic Drug User Fees Lower Than Expected, Thanks To Higher Volume
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
Generic Drug Facilities Guidance Details Who Self-Identifies, And Who Pays Fees
GDUFA Guidance Offers Peek At Generic Drug User Fee Levels
Generic Facility Fee Unlikely To Be Charged Until A Few Months After GDUFA Implementation
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

Topics

Advertisement
UsernamePublicRestriction

Register

PS074547

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel